Follow-up of Blood-Pressure Lowering and Glucose Control in Type 2 Diabetes | Zendy

Sophia Zoungas | Zendy; John Chalmers | Zendy; Bruce Neal | Zendy; Laurent Billot | Zendy; Qiang Li | Zendy; Yoichiro Hirakawa | Zendy; Hisatomi Arima | Zendy; Helen Monaghan | Zendy; Rohina Joshi | Zendy; Stephen Colagiuri | Zendy; Mark E. Cooper | Zendy; Paul Glasziou | Zendy; Diederick E. Grobbee | Zendy; Pavel Hamet | Zendy; Stephen Harrap | Zendy; Simon Heller | Zendy; Lisheng Liu | Zendy; Giuseppe Mancia | Zendy; Michel Marre | Zendy; David R. Matthews | Zendy; Carl Erik Mogensen | Zendy; Vlado Perkovic | Zendy; Neil R Poulter | Zendy; Anthony Rodgers | Zendy; Bryan Williams | Zendy; Stephen MacMahon | Zendy; Anushka Patel | Zendy; Mark Woodward | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Follow-up of Blood-Pressure Lowering and Glucose Control in Type 2 Diabetes

Author(s) -

Sophia Zoungas,

John Chalmers,

Bruce Neal,

Laurent Billot,

Qiang Li,

Yoichiro Hirakawa,

Hisatomi Arima,

Helen Monaghan,

Rohina Joshi,

Stephen Colagiuri,

Mark E. Cooper,

Paul Glasziou,

Diederick E. Grobbee,

Pavel Hamet,

Stephen Harrap,

Simon Heller,

Lisheng Liu,

Giuseppe Mancia,

Michel Marre,

David R. Matthews,

Carl Erik Mogensen,

Vlado Perkovic,

Neil R Poulter,

Anthony Rodgers,

Bryan Williams,

Stephen MacMahon,

Anushka Patel,

Mark Woodward

Publication year - 2014

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1407963

Subject(s) - medicine , glycated hemoglobin , indapamide , blood pressure , type 2 diabetes , hazard ratio , diabetes mellitus , placebo , perindopril , randomized controlled trial , clinical endpoint , confidence interval , surgery , endocrinology , alternative medicine , pathology

In the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) factorial trial, the combination of perindopril and indapamide reduced mortality among patients with type 2 diabetes, but intensive glucose control, targeting a glycated hemoglobin level of less than 6.5%, did not. We now report results of the 6-year post-trial follow-up.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research